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Aims To identify correlates of impaired quality of life (QOL), anxiety, and depression in patients with an
implantable cardioverter-defibrillator (ICD).
Methods and results Surviving patients (n ¼ 610) who received an ICD in our institution since 1989 com-
pleted the Short Form Health Survey (SF-36) and the Hospital Anxiety and Depression Scale. Mean age
was 62.4 years with 18% females. In a multivariate logistic regression analysis, symptomatic heart
failure was the most important correlate of impaired QOL (SF-36) across all eight subscales [odds
ratios (ORs) ranging from 5.21 to 22.53)], whereas psychotropic medication, age, comorbidity, amiodar-
one, and ICD shocks all correlated to a lesser extent. Symptomatic heart failure was also the most
dominant correlate of anxiety [OR 5.15 (3.08–8.63), P , 0.001] and depression [OR 6.82 (3.77–
12.39), P , 0.001]. Implantable cardioverter-defibrillator shocks correlated less yet significantly with
anxiety [OR 2.21 (1.32–3.72) P , 0.01] and depression [OR 2.00 (1.06–3.80), P , 0.05].
Conclusion Symptomatic heart failure was the single most important clinical correlate of impaired QOL,
anxiety, and depression, with ICD shocks playing only a secondary role. This suggests that comorbidity











Treatment with an implantable cardioverter-defibrillator
(ICD) has been shown to reduce mortality significantly in
patients at risk of sudden arrhythmic death1 and in combi-
nation with cardiac resynchronization therapy (CRT) also
to relieve chronic heart failure (CHF) symptoms, leading to
improved quality of life (QOL), exercise capacity, and
cardiac function.2 However, the well-being of an ICD
patient can be negatively influenced by a number of
factors apart from the risk of dying suddenly or having
painful shocks, including the underlying heart disease (e.g.
ischaemic vs. non-ischaemic), comorbidity (e.g. CHF), pre-
sence of the ICD (e.g. cosmetic), social or professional
restrictions (e.g. driver’s license), a negative effect on
partner and family life or non-optimal information and
support from the healthcare system.
Although there has been a strong focus on optimizing the
clinical aspects of ICD therapy, only more recently attention
has been paid to the psychological issues. Importantly, a
subset of patients is prone to experience high levels of ICD
concerns, with a negative impact on acceptance of the
ICD.3 Thus, when advocating the widespread use of ICDs,
particularly in asymptomatic patients, the psychological
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impact of living with an ICD should also be considered,
because the full benefits of ICD therapy can only be achieved
if the patient’s QOL and emotional well-being are preserved.
To date, no studies have evaluated QOL, anxiety, and
depression and their correlates in a large cross-sectional
population of patients with an ICD. Hence, we approached
all surviving patients having received an ICD in our insti-
tution, with a view to examine the potential influence of a
multitude of factors on the QOL and psychological health
of the ICD patient.
Methods
Patients
The study population consists of all patients implanted with an ICD
at the Aarhus University Hospital (Skejby) since 1989 and still alive
on 1 November 2006. Patients with a first ICD implant within the last
3 months were not included. In 95% of the patients, the main indi-
cation for ICD was secondary prevention, as primary prevention
was not generally implemented in Denmark before 2007. A flow
chart of the patient selection is presented in Figure 1.
All surviving patients received a questionnaire by mail, which they
were asked to complete and return in a self-addressed, stamped
envelope. If the questionnaire was not returned within 2 weeks, a
reminder was sent including a duplicate of the questionnaire. The
patient was asked to complete a number of questions on clinical
and demographic data and a set of standardized and validated
psychological questionnaires. The study was conducted according
to the Helsinki Declaration.
Demographic and clinical variables
Data were retrieved from the patients’ medical records and the
Danish ICD Registry4 and from purpose-designed questions in the
questionnaire. All re-operations caused by device or lead malfunc-
tioning or infection, as registered by the Danish ICD Registry,4
were considered as complication to ICD therapy. Comorbidity (e.g.
gait, diabetes, muscular dystrophy, stroke, cancer, pulmonary
disease, and renal insufficiency) and number of ICD shocks were
based on self-report. Symptomatic CHF was determined using the
Minnesota living with heart failure (MLHF) questionnaire.5 The
21-item MLHF is a valid and reliable, disease-specific measure of
QOL, with items scored on a 6-point Likert scale from 0 (no) to 5
(very much). The total MLHF score ranges from 0 to 105, with a
lower score indicating good QOL. Dichotomization was undertaken
in order to enhance the interpretation of the results in clinical
practice.6 An MLHF score above 40 represents New York Heart
Association (NYHA) classes III–IV (i.e. symptomatic CHF).7 As the
75% upper percentile in our data was 41, we used at cut-off value
of .40 as a marker of symptomatic CHF.
Figure 1 Flowchart for the study group.
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Anxiety and depression symptoms
The 14-item Hospital Anxiety and Depression Scale (HADS)& (see
Appendix) was used to assess the symptoms of anxiety (seven
items) and depression (seven items).8 Items are answered on a
4-point Likert scale ranging from 0 to 3 (score range 0–21). The
HADS is a valid and reliable instrument across countries in cardiac
and non-cardiac populations,9–11 with a recent review demonstrat-
ing that a cut-off 8 on both subscales represents probable clinical
levels.11 An advantage of the use of HADS in the context of patients
with somatic disease is that it is devoid of somatic items and hence
more likely to reflect real depressive symptoms rather than under-
lying disease.10
Quality of life
The Short Form Health Survey (SF-36) was used to assess the QOL.12
The SF-36 is a generic QOL measure comprising eight subdomains:
role physical functioning, role emotional functioning, physical func-
tioning, mental health, vitality, social functioning, bodily pain, and
general health. Scale scores are obtained by summing the items
together within a domain, dividing this outcome by the range of
scores, and then transforming the raw scores to a scale from 0 to
100. A higher score on the SF-36 subdomains represents better func-
tioning, with a high score on the bodily pain scale indicating the
absence of pain. The scale has good reliability with Cronbach’s
alpha ranging from 0.65 to 0.96 for all subscales.13
Statistics
Continuous variables were compared with Student’s t-test for inde-
pendent samples and discrete variables with the x2 test. In multi-
variable logistic regression, we analysed demographic and clinical
factors as correlates of impaired QOL, anxiety, and depression.
Prior to analyses, we dichotomized all QOL scores using the lower
tertile on the SF-36 to indicate impaired QoL. In all analyses, we
entered age, gender, years in ICD therapy, complication to ICD
therapy, smoking, ICD shocks, comorbidity, amiodarone, other anti-
arrhythmic medication, psychotropic medication, living with a
spouse, ischaemic vs. non-ischaemic aetiology for ICD, and CHF
(as expressed by MLHF . 40), which were selected a priori on the
basis of the literature. A P-value less than 0.05 was chosen to indi-
cate statistical significance, and all tests were two-tailed. Odds
ratios (ORs) with their corresponding 95% confidence intervals
(CIs) are reported for the logistic regression analyses. All analyses
were performed using SPSS 13.0 for Microsoft Windows.
Results
Of the 723 potentially eligible patients, 624 returned the
questionnaire (response rate 86%) and data were adequate
for 610 patients (84%). Patients included in the study were
slightly older 62.4+14.2 vs. 58.8+16.2 (P , 0.05, Stu-
dent’s t-test), and those included also had a higher preva-
lence of ischaemic aetiology for ICD therapy (63 vs. 52%,
P , 0.05, x2), compared with those not included. Years of
ICD treatment, gender, proportion of cardiac resynchroniza-
tion therapy device and defibrillator (CRT-D), and compli-
cations were evenly distributed (data not shown).
Baseline characteristics
Basic demographic and clinical data for the 610 patients who
constituted the study group (Figure 1) are shown in Table 1.
The mean age was 62.4 years, which is comparable with
other studies, whereas male gender was more dominant
(82%) in comparison with 76–80% seen in other major
studies.14,15 Only 110 patients (18.0%) were implanted
with a CRT-D and 578 patients (95%) had secondary
prevention as indication, reflecting the historical data. A
total of 51 (8.4%) patients had device-related complications
such as infection, premature end of life of the device, lead
fracture, and so on, causing re-operation. Major findings
were ischemic heart disease in 384 patients (63.0%), comor-
bidity in 134 patients (22.0%), CHF in 150 patients (24.6%),
and treatment with amiodarone in 142 patients (23.3%). As
expected, patients with CHF, as measured by an MLHF
score .40, were significantly more often treated with
CRT-D, CHF medication, and amiodarone (Table 2). The
only exception was b-blockers, which was evenly distribu-
ted. A total of 263 patients (43.1%) reported having experi-
enced ICD shocks, with 96 patients (15.7%) having received
more than three shocks.
Correlates of impaired quality of life
The dominant independent correlate of impaired QOL, as
shown in Table 3, was CHF, which was an independent corre-
late across all eight subscales of the SF-36. Other indepen-
dent correlates of impaired QOL were psychotropic
medication (six of eight subscales), age (four of eight sub-
scales), comorbidity (four of eight subscales), and amiodar-
one (two of eight subscales). Interestingly, ICD shocks only
had a negative effect on one of the eight QOL subscales
of the SF-36 (i.e. physical functioning), and no effect
was seen on ICD-related complications or years with ICD
therapy.
Correlates of anxiety and depression
Chronic heart failure and, to a lesser degree, ICD shocks
were correlates of symptoms of anxiety and depression
(Table 4), with women being likely to report anxiety than
men and patients using psychotropic medication more
likely to report depression. Again, ICD-related complications
and years with ICD therapy were not associated with anxiety
or depression.
Discussion
Despite several clinical studies having documented that ICD
treatment significantly reduces sudden arrhythmic death,
the implantation rate both for primary and secondary pre-
vention shows a worldwide variation.16 With the addition
of CRT to ICD therapy, the benefit of ICD implantation
should be even more advantageous for larger patient
groups. The extremes are the USA in comparison with the
less-developed countries, but even between socio-
economically comparable European countries, implantation
rates vary considerably.17 The differences in the rate of
ICD implantation can, therefore, only partly be attributed
to the availability of economical and medical resources,17
whereas it has been suggested that local guidelines, psycho-
logical and ethical factors may also play a role.18
For many physicians, there seems to be an ethical barrier
blocking implementation of the international guidelines for
ICD implantation. This barrier has been suggested to be
due to the physician’s concern about the psychological
strain on the ICD patient, especially in the case of multiple
shocks or device-related complications.18 However, some of
the principal findings of our study are, as also found by
others,19 that shock therapy leads to increased anxiety,
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although the influence on depression is less clear. More
importantly, in the present study, the negative effect
induced by shock therapy on QOL was only documented for
one of eight subscales of the SF-36. In addition, in contrast
to another but considerably smaller study,20 neither ICD-
complications nor years with ICD therapy correlated with
impaired QOL or anxiety and depression. The rather low
complication rate of 8.4% found in this study21,22 may
partly explain the latter finding, thereby also stressing the
importance of high medical standards. Taken together,
these results show that in our large cohort of ICD patients,
in general, ICD therapy was well tolerated also from a
psychological point of view.
In the current study, we used the MLHF to evaluate the
severity of CHF rather than the NYHA classification system,
as the validity and reliability of the latter classification
system are the subject of some debate.23 The MLHF seems
to be a good and integrated measure of both physical and
mental impairment due to CHF.24 Furthermore, the simul-
taneous CHF assessment by MLHF and sampling of SF-36
Table 1 Baseline characteristics for eligible patients with psychological data (n ¼ 610)
No. of patients Percentage of total (%) Questionnaire scores, Mean (SD)
Demographics
Female gender 108 17.7
Age, mean (range) 62.4 (8–85)
Living with a spouse 463 75.9
Clinical
Years in treatment, mean (range) 4.8 (0.4–15.9)




Ischaemic heart disease 384 63.0
Idiopathic ventricular fibrilation 5 0.8
Hypertrophic cardiomyopathy 11 1.8
Dilated cardiomyopathy 44 7.2
Arrhythmogenic right ventricle 13 2.1
Cardiomyopathy, other 71 11.6
Congenital heart disease 11 1.8
Valvular heart disease 10 1.0
Congenital long QT 4 0.7
Primary electrical disease, other 9 1.5
Unknown 48 7.9
Secondary prevention as ICD indication 578 94.8
CHF (MLHF.40) 150 24.6
ICD shock (1 shock) 263 43.1
ICD shock (4 shocks) 96 15.7
Comorbidity 134 22.0




Loop diuretics 274 44.9
Aldosterone antagonist 184 30.2
Digoxin 96 15.7
Amiodarone 142 23.3
Other anti-arrhythmics 13 2.1
Psychotropics 78 12.8
Psychological
Anxietya 115 18.9 4.3 (4.1)
Depressiona 77 12.6 3.4 (3.4)
Quality of lifeb
Impaired physical functioning 184 31.1 65.0 (27.7)
Impaired role physical functioning 17 2.1 48.3 (43.5)
Impaired role emotional functioning 117 19.1 67.6 (39.5)
Impaired mental health 196 32.1 78.3 (18.8)
Impaired vitality 187 30.7 59.3 (25.6)
Impaired social functioning 194 31.8 83.7 (23.8)
Impaired bodily pain 196 32.1 78.1 (26.3)
Impaired general health 202 33.1 58.5 (24.1)
aCut-off  8, as recommended by Bjelland and colleagues.9
b‘Impaired’ indicates lower tertile of the total score of the subscale.
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and HADS data is an advantage of this study, which evaluates
the interactions between CHF and QOL and anxiety and
depression.
Symptomatic CHF, seen in 25% of the patients, was the
strongest correlate of impaired QOL, associated with all
SF-36 subscales. This corresponds well with the findings
from studies of CHF patients without ICDs.25,26 It also stres-
ses the importance of optimizing CHF medication and adding
CRT to ICD therapy in patients with indications for CRT to
achieve the additive effect of CRT on top of conventional
heart failure drug therapy.27
Amiodarone, a class 3 anti-arrhythmic drug primarily used
for treatment-resistant tachyarrhythmias, was in the
present study independently correlated with impaired QOL
on four of eight QOL subscales, likely due to its many and
troublesome side effects.28 Although amiodarone is a
proven effective adjunct drug therapy in ICD patients,29
several long-term studies have also shown that it is poorly tol-
erated with subsequent low compliance.29,30 This has also
been found in other studies in non-ICD patients28 and thus
suggests a restricted use of amiodarone whenever possible.
Clinical levels of anxiety and depression are seen in
25–30% of ICD patients,31 which is slightly more than in
the current study. Similar to some32,33 but not all
studies,34 we found that CHF and ICD shocks were significant
correlates of anxiety and depression. Like others34 we also
found that females were more likely to report anxiety com-
pared with males, and that the use of psychotropic medi-
cation was related to depression.
Any physician dealing with ICD therapy is concerned about
the constraint forced upon health economics and the com-
plication rate related to device implantation and therapy35
and the logistics connected to the rapidly increasing
number of implants and follow-ups. Everybody can recall
single patient cases with multiple shock therapies, being
appropriate or inappropriate, leaving the patient and the
family in a psychological traumatized state. However,
overall findings of the current study indicate that aside
from the above-mentioned troublesome but single cases,
ICD treatment seems to be well accepted and tolerated by
the vast majority of patients. Therefore, whenever suffi-
cient health economics is available, ICD treatment should
be offered to all eligible patients also as a primary preven-
tion measure. This recommendation is supported by cost–
benefit analyses, demonstrating that ICD treatment is
Table 2 Relationship between CHF as indicated by MLHF and
other surrogates for CHF





CRT-D 70 (15.2%) 40 (26.7%) 0.002
b-blocker 375 (83.3%) 115 (78.8%) 0.21
ACE-inhibitors 299 (67.0%) 108 (75.0%) 0.07
Loop diuretics 173 (38.4%) 101 (67.8%) ,0.000
Aldosterone
antagonist
121 (27.1%) 63 (42.3%) ,0.000
Digoxin 63 (14.0%) 33 (22.3%) 0.017
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found competitive in comparison with other already fully
implemented invasive cardiac strategies.36–39
Our study is addressing that which is beneficial to the
majority of patients and tends to ignore the special needs
of individual patients. Pedersen and colleagues have in a
number of studies identified a subgroup of ICD patients
who are at risk for increased anxiety and depression and
poor QOL, with the distressed (Type D) personality and a
high score on ICD concerns characterizing these
patients.19,34 Besides standard ICD indications based on
rigid clinical criteria, this calls for a more patient-specific
selection procedure before ICD implantation, with more
focus on the individual need of the patient both at the
time of evaluation and implantation and in the post-
hospitalization follow-up phase. More studies are warranted
in this direction in order to be able to identify high-risk
patients who may need further support and adjunctive inter-
vention, e.g. of a psychosocial nature. Preliminary evidence
from a recent review indicates that such intervention may
successfully reduce levels of anxiety.40
The results of this study should be interpreted with some
caution, as the cross-sectional design of the study does not
allow for the inference of cause and effect. In addition,
symptomatic CHF was assessed by means of a proxy
measure, namely the MLHF questionnaire and we had no
information on left ventricular ejection fraction (LVEF), as
a measure of disease severity, which could potentially
serve as a confounder, although LVEF had no effect on
patient-centred outcomes in other studies.3,19 Furthermore,
some clinical variables were obtained by means of self-
report, which may be subject to bias. In addition, the
majority of patients had a secondary indication for ICD
implantation, reflecting the historical data. This might
imply that the results of the current study may not necess-
arily be generalizable to ICD patients seen in clinical cardi-
ology practice today, since the number of patients with a
primary indication is increasing. Nevertheless, studies
examining the influence of indication on patient-centred
outcomes, such as QOL, anxiety and depression, have
found no support for an effect of indication on these out-
comes, including on acceptance of the device.3,32,41,42
Despite these limitations, this study also has several
strengths, including the relatively high response rate and
that this, to our knowledge, is the largest study of ICD
patients to report on a broad range of patient-centred out-
comes, including QOL, anxiety, and depression.
In conclusion, the present study documents that ICD
therapy, in general, is very well accepted by ICD patients,
with CHF being the dominant correlate of impaired QOL.
Despite ICD implantation reducing cardiac arrhythmic
death, this treatment modality is very unevenly distributed
among countries, a fact that cannot be fully explained by
socio-economical differences. Ethical and psychological
factors may play an important role in determining to what
extent ICD treatment is implemented in the national
health strategies. As a consequence, there seems to be a
need for further education and information of the health
community, so that ICD treatment is not withheld on subjec-
tive reasons, but is offered to all eligible patients including
as primary prevention.
In addition, focus should be directed towards improving
the QOL and reducing anxiety and depression in a subgroup
of patients, particularly those with symptomatic CHF.
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